Drug Trial Radar · NCT07140523
A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA
Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Sep 16, 2025
Primary completion
Jun 30, 2026
Study completion Oct 31, 2026
Sponsor
- Lead sponsor
- Sirius Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter, randomized, open-label, parallel group, blinded endpoint evaluation, active-controlled, dose-finding study.This study is designed to compare the efficacy and safety of 3 dose levels of SRSD107 and enoxaparin 40 mg daily in subjects undergoing elective primary unilateral TKA.
Conditions
- Venous Thromboembolism
Interventions
SRSD107Drug
SRSD107 is an investigational siRNA product for anticoagulants.
enoxaparinDrug
Enoxaparin is a low molecular weight heparin \[LMWH\] indicated for Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of total venous thromboembolism (VTE) eventsTime frame: From the date of surgery through 12±2 days after surgery.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Nové Město na Moravě
Nové Město na Moravě, Czechia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.